UK health-technology assessor and guidance body
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Cambridge and ICR researchers show NICE criteria miss up to 95% of women under 50 who will develop breast cancer within 10 years. A new model called Boadicea identifies eight times as many high-risk women, prompting calls for review and investment to implement multifactorial risk assessment across the NHS.
Athletes and patients have urged Downing Street to appoint a national brain cancer lead and boost research funding. The Rare Cancers Bill is seen as a step forward but not enough, with calls for faster action in light of Commonwealth Games coverage and ongoing treatment campaigns.
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
England has authorised Enhertu for routine NHS use for HER2‑low metastatic breast cancer, ensuring access for about 1,000 women annually. The decision follows a previous rejection over cost‑effectiveness and builds on a deal between NICE and drug makers AstraZeneca and Daiichi Sankyo. Scotland has already provided access since 2023.
The Guardian reports a government review has proposed triaging ADHD patients to a needs-based system, offering targeted support without necessarily requiring a formal diagnosis. The plan aims to relieve NHS waiting lists and focus help on those most in need, while raising concerns about potential rationing of care.